A Review of Incretin Therapies Approved and in Late|Stage ...

The Safety of Incretin-Based Therapies-Review of the Scientific ...

Incretin therapies reduce weight gain, minimize hypoglycemia, decrease inflammation, and are cardioprotective in preclinical studies. However, data permitting ...

Glucagon-like peptide 1-based therapies for the treatment of type 2 ...

A synthetic dual-acting GIP and GLP-1 receptor agonist (tirzepatide) is available for the treatment of hyperglycemia in patients with type 2 ...

European Journal of Internal Medicine

This review focuses on the efficacy and safety of incretin therapies, and the ... approved therapeutic agent in the incretin class of medications, and acts ...

Incretin Therapy: A Short Review

Incretin-based therapies address the beta cell dysfunction and abnormal glucagon secretion found in type 2 diabetes. ... Often used in combination ...

is there preclinical evidence that incretin-based therapies alter ...

Incretin-based therapies appear to offer many advantages over other approaches for treating type 2 diabetes. Some preclinical studies have suggested that ...

GLP-1 single, dual, and triple receptor agonists for treating type 2 ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose ...

The GLP-1 journey: from discovery science to therapeutic impact - JCI

(A) Data revealing GLP-1–stimulated insulin secretion supported the approval of the first GLP-1RA for the treatment of T2D in 2005. Nine years ...

Incretin Therapies for Patients with Type 2 Diabetes and Chronic ...

Incretin effects on structural kidney damage observed in diabetic kidney disease. ... (b) Treatment with incretin-based therapies can ameliorate the structural ...

Effects of Incretin-Based Therapies on Diabetic Microvascular ...

Incretins induce insulin secretion and suppress glucagon secretion, which improve hyperglycemia and insulin resistance [16]. As a result, ...

What is the pipeline for future medications for obesity? - Nature

The safety profile of retatrutide was consistent with that of other incretin-based therapies. Transient and mostly mild-to-moderate ...

Mechanisms and clinical applications of incretin therapies...

FIGURE 2: Incretin effects on structural changes observed in diabetic kidney disease. A. ... B. Treatment with incretin-based therapies can ameliorate the ...

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative ...

The incretin effect, which has been attributed to GLP-1 and GIP, is recognized as a significantly greater insulin secretory response to oral glucose compared to ...

Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to ...

Incretin-based therapies are effective glucose-lowering drugs that have an increasing role in the treatment of type 2 diabetes because of ...

Treating Patients With Type 2 Diabetes -- Incretin-Based Therapies

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose ...

Incretin-based medications for type 2 diabetes: an overview of reviews

The first incretin-based medication approved was the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide, receiving US Food and Drug. Administration (FDA) ...

Role of incretins and glucagon receptor agonists in metabolic ...

Importantly, this study provides a summary of clinical trials analyzing the effectiveness and safety of incretin receptor agonists in MASLD ...

Comparison of efficacy between incretin-based therapies for type 2 ...

Incretin based therapies are available as either incretin mimetics (also called GLP-1 agonists) or incretin enhancers (DPP-4 inhibitors).

Incretin-Based Drugs and the Risk of Acute Pancreatitis

With a combined cohort of more than 1.5 million patients with type 2 diabetes, our findings suggest that use of incretin-based drugs is not ...

Incretins (GLP-1 receptor agonists and dual/triple agonists) and the ...

Increased glucose-dependent insulin release and reduced glucagon levels in response to GLP-1 (glucagon-like peptide 1) agonist therapy are associated with a ...

Safety and Efficacy of Incretin-Based Therapies in Patients With ...

Our meta-analysis confirms several clinically relevant effects of the incretin-based therapies, including effective reduction of glycemia ...